EUROAPI : H1 2025 Results Presentation (euroapi h1 2025 results presentation)

About this update from Euroapi Sa

euraAPi Active Solutions for Health i ii ies Introduction David Seignolle Chief Executive Officer H1 2025 Key Figures €37.8m 60% dedicated to growth Net Sales Core EBITDA €412.1m (8.2)% Sanofi €176.1m -15.3% Other Clients €236.0m -2.0% €39.5m Core EBITDA margin 9.6% EBITDA CAPEX €5.0m €39.3m exceptional items H1 2025 key takeaways Thorough execution of the FOCUS-27 plan Resilience Sales to Sanofi APIs sales affected by unfavorable comparison base and lower sales from Sevelamer Strong performance of the CDMO activity driven by large-scale contracts in anti-infective and skin care Sales to Other Clients Solid growth in Opioids and unfavorable phasing in Vitamin B12 sales Gradual ramp-up of recent CMO projects more than offset by the downsizing of pre-carve out contracts, ongoing derisking of the portfolio Discipline Reduced Personnel Costs Sustained savings in external spendings Tight management of Operating Working Capital Controlled and targeted CAPEX Execution Successful divestment of the Haverhill site to Particle Dynamics API discontinuation program progressing as planned Agreement on IPCEI signed with the French Government Attention : This is an excerpt of the original content. To continue reading it, access the original document here .

View stock analysis, news, and events for Euroapi Sa